Observational studyESC heart failure2022
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity.
Observational study in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Machine learning-enhanced baseline risk prediction models for cancer therapy related cardiac dysfunction: a systematic review and critical appraisal of methodological quality.European heart journal. Digital health · 2026Article
- Cardiovascular Care in Multiple Myeloma: A Comprehensive Review and Integrated Systems-Based Approach from a UK Cardio-Oncology Centre of Excellence.Current cardiology reports · 2026Review
- Cardiotoxicity of Targeted Therapies in Hematologic Malignancies: From Molecular Mechanisms to Clinical Management.Current treatment options in oncology · 2026Review
- Healthcare Management in Cardio-Oncology, Clinical Strategies and Future Perspectives: A Narrative Review.Healthcare (Basel, Switzerland) · 2025Review
- Development of an Electronic Medical Record-Based Score for Heart Failure Prediction in Cancer Survivors.JACC. Advances · 2025Article
- Evolving Cardioprotective Strategies in Cardio-Oncology: A Narrative Review.Current cardiology reports · 2025Review
- Cardiovascular risk in cancer patients: initial experience from a cardio-oncology clinic in Mexico.Archivos de cardiologia de Mexico · 2025Article
- Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients.Journal of cardiovascular development and disease · 2025Review
- Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?ESC heart failure · 2025Article
- Validation of novel predictors for early detection of cancer therapeutics-related cardiac dysfunction.Future cardiology · 2025Article
- Advances in Cardioprotection Strategies: Focusing on Breast Cancer and Beyond Through Novel Biomarkers and Pharmacological Approaches.European cardiology · 2025Review
- Artificial intelligence: Applications in cardio-oncology and potential impact on racial disparities.American heart journal plus : cardiology research and practice · 2024Article
- Cardiovascular Considerations Before Cancer Therapy: Gaps in Evidence andJACC. CardioOncology · 2024Review
- Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score.Cardio-oncology (London, England) · 2024Article
- Joint effects of CD8A and ICOS in Long QT Syndrome (LQTS) and Beckwith-Wiedemann Syndrome (BWS).Journal of cardiothoracic surgery · 2024Article
- Right ventricle involvement in patients with breast cancer treated with chemotherapy.Cardio-oncology (London, England) · 2024Article
- The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia.Hematology reports · 2024Article
- Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond.Biomolecules · 2024Review
- Mitochondrial Dysfunction in Cardiotoxicity Induced by BCR-ABL1 Tyrosine Kinase Inhibitors -Underlying Mechanisms, Detection, Potential Therapies.Cardiovascular toxicology · 2023Review
- Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation.Scientific reports · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukaemia (CML) can cause cardiovascular adverse events. So far, the Systematic Coronary Risk Evaluation (SCORE) charts of the European Society of Cardiology (ESC) have been used to identify cancer patients at increased cardiovascular risk. The primary aim of our study was to evaluate the usefulness of the new cardiovascular risk assessment model proposed by the Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the ESC in collaboration with the International Cardio-Oncology Society (ICOS) to stratify the cardiovascular risk in CML patients, compared with SCORE risk charts. The secondary aim was to establish the incidence of adverse arterial events (AEs) in patients with CML treated with TKIs and the influence of preventive treatment with aspirin. METHODS AND
resultsA retrospective single-centre observational study was carried out on 58 patients (32 men and 26 women; mean age ± SD: 59 ± 15 years) with CML treated with TKIs for a median period of 43 ± 31 months. Cardiological evaluation was performed and cardiovascular risk was estimated with SCORE risk charts and with the new risk assessment tool proposed by HFA/ICOS. AEs were recorded. According to SCORE charts and the new HFA/ICOS risk stratification tool, respectively, 46% (Group A1) and 60% (Group A2) of patients were at high-very high risk, and 54% (Group B1) and 40% (Group B2) at low-moderate risk. AEs were significantly more frequent in Group A1 than Group B1 (P value < 0.01) when considered overall; they were significantly more frequent in Group A2 than Group B2 either overall or considered individually. HFA/ICOS risk stratification tool was significantly more sensitive than SCORE (P < 0.01) in identifying patients at higher risk of cardiovascular toxicity. In addition, we did not find AEs in patients pretreated with aspirin.
conclusionsThe new HFA/ICOS risk stratification model allows a more tailored cardiovascular risk stratification in patients with CML and it is more sensitive than SCORE charts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.